NASDAQ
1.37USD
+0.01 (+0.74%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
99.1M
P/E
—
EPS
—
Beta
-0.30
52W range
0.872-2.99
Day range
1.35–1.37
Open
1.35
Prev close
1.36
Volume
575.3K
Avg volume
1.1M
Dividend
0.00
IPO
2021-04-16
https://invezz.com/news/2026/08/24/citi-sees-up-to-410-upside-in-2-biotech-stocks-is-the-risk-worth-it/ · 8/24/2026+0.80
https://www.globenewswire.com/news-release/2026/06/05/3307662/0/en/Biomea-Fusion-Presents-New-Clinical-and-Translational-Data-for-Icovamenib-at-the-American-Diabetes-Association-ADA-86th-Scientific-Sessions-and-Announces-Expansion-of-Ongoing-Phase.html · 6/5/2026+0.80
https://www.globenewswire.com/news-release/2026/05/05/3288402/0/en/Biomea-Fusion-Announces-Poster-Presentations-of-Icovamenib-at-the-American-Diabetes-Association-ADA-86th-Scientific-Sessions.html · 5/5/2026+0.80
https://seekingalpha.com/article/4895293-biomea-fusion-inc-bmea-discusses-top-line-results-from-covalentminus-112-trial-of-icovamenib · 4/28/2026+0.50
https://www.globenewswire.com/news-release/2026/04/27/3282109/0/en/Biomea-Fusion-Announces-Positive-52-Week-Results-from-Phase-2-COVALENT-112-Trial-in-Type-1-Diabetes-Showing-C-Peptide-Improvement-and-Durability-Following-12-Weeks-of-Icovamenib-Tr.html · 4/27/2026+0.90
https://www.globenewswire.com/news-release/2026/03/24/3261720/0/en/Biomea-Fusion-Reports-Full-Year-2025-Financial-Results-and-Corporate-Highlights.html · 3/24/2026+0.80
https://www.defenseworld.net/2026/01/17/biomea-fusion-spotlights-diabetes-obesity-pipeline-at-jpmorgan-conference-sets-2026-milestones.html · 1/17/2026+0.30
https://www.globenewswire.com/news-release/2025/10/27/3174503/0/en/Biomea-Fusion-Announces-First-Patient-Dosed-in-Phase-I-Study-of-BMF-650-a-Next-Generation-Oral-GLP-1-Receptor-Agonist.html · 10/27/2025+0.80
https://www.globenewswire.com/news-release/2025/09/16/3150644/0/en/Biomea-Fusion-Presents-Data-Demonstrating-Enhanced-Preclinical-Activity-of-Icovamenib-in-Combination-with-Semaglutide-in-Type-2-Diabetes-T2D-Animal-Model-at-the-61st-EASD-Annual-Me.html · 9/16/2025+0.80
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
